Merus NV

Merus NV

Merus NV

Overview
Date Founded

2003

Headquarters

Yalelaan 62,Utrecht 3584 CH

Type of Company

Public

Employees (Worldwide)

98

Industries

Biotechnology

Company Description

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Contact Data
Trying to get in touch with decision makers at Merus NV? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Executive Vice President, General Counsel & Head of Utrecht

Senior Vice President & Chief Technology Officer

Senior Vice President & Chief Development Officer

Senior Vice President & Chief Medical Officer

Executive Vice President & Chief Medical Officer

Chief Business Officer & Head of Merus US

Secretary & Head-Legal Europe

Vice President, Investor Relations & Corporate Communications

Secretary to the Supervisory Board

Paths to Merus NV
Potential Connections via
Relationship Science
You
Merus NV
Owners & Shareholders
Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Details Hidden

Medicxi invests in biopharma companies located in Europe. The firm participates in early and late stage capital requirements.

Details Hidden

Sofinnova Ventures(Sofinnova Ventures) invests in life science and technology companies located in the US and Europe. The firm targets companies operating in the fields of healthcare, clinical stage drug development, biopharmaceutical products, components, systems, and software. It provides financing for early and later stage capital requirements with investment size ranges from $15 to $35 million.

Recent Transactions
Details Hidden

Merus NV raised money in a private placement transaction

Details Hidden

Merus NV raised money in a private placement transaction

Details Hidden

Merus NV raised money in a private placement transaction

Transaction Advisors
Escrow Agent

Advised onMerus NV issued USD Common Shares

Underwriter

Advised onMerus NV issued USD Common Shares

Underwriter

Advised onMerus NV issued USD Common Shares

Advisors & Consultants
Publicist

Managing Director at Argot Partners LLC

Publicist

Professional at Scient Public Relations

Clients

Incyte's vision is to become a leading drug discovery, development and commercial company by building a proprietary product pipeline of novel small molecule drugs for serious unmet medical needs. We have experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders. Our pipeline is focused on oncology and inflammation and includes compounds in various stages of development. Our lead product, JakafiĀ® (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the United States for the treatment of intermediate or high-risk myelofibrosis (please see Full Prescribing Information and Important Safety Information for Jakafi) and is in development as a potential treatment for other cancers. We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. Through strategic collaborations with Novartis and Eli Lilly, we are advancing the global development of two of our JAK1 and JAK2 inhibitor programs. Incyte's corporate headquarters is located in Wilmington, Delaware

Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.

Betta Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of anticancer targeted drugs. Its product, icotinib hydrochloride tablet, provides treatment for non-small cell lung carcinoma disease. The company was founded by Lie Ming Ding on January 7, 2003 and is headquartered in Hangzhou, China.

Key Stats and Financials As of 2019
Market Capitalization
$368M
Total Enterprise Value
$106M
Earnings Per Share
$-2.28
Revenue
$31.1M
Net Profit
$-55.2M
EBITDA
$-57.5M
EBITDAMargin
-184.75%
Total Debt
$5.25M
Total Equity
$131M
Enterprise Value Sales
3.41x
TEVNet Income
-1.93x
Debt TEV
0.05x
Three Year Compounded Annual Growth Rate Of Revenue
175.38%
Investors
Details Hidden

Sofinnova Ventures(Sofinnova Ventures) invests in life science and technology companies located in the US and Europe. The firm targets companies operating in the fields of healthcare, clinical stage drug development, biopharmaceutical products, components, systems, and software. It provides financing for early and later stage capital requirements with investment size ranges from $15 to $35 million.

Details Hidden

Tekla Capital Management primarily focuses on healthcare investing. Their funds invest in public and private growth equities in the healthcare and life sciences industries.

Details Hidden

BBA primarily invests client assets in public and private securities and related assets and revenue streams of life sciences and health care companies and cash management investments. These securities include, but are not limited to: equity securities, including exchange-listed and over-the-counter securities; warrants; corporate debt securities, including convertible bonds; options contracts on securities; ETFS; and money market funds. BBA focuses on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. The firm adheres to a fundamentally-driven approach to life sciences investing. They typically take large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

MacroGenics, Inc. Pharmaceuticals - Rockville, MD

MacroGenics is a leader in the discovery and development of innovative medicinces that utilize our next generation antibody-based technologies. Our team of 150+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases. Our products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe. Our innovative product candidates leverage our fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three proprietary technology platforms: Our Dual-Affinity Re-Targeting (DARTā„¢) platform enables us to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule; Our Fc Optimization platform enhances the natural immune system's ability to mediate killing of cancer cells; and Our Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy.

Genmab A/S Pharmaceuticals - Copenhagen, Denmark

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Merus NV. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Merus NV's profile does not indicate a business or promotional relationship of any kind between RelSci and Merus NV.